ArticleAsian Pacific journal of cancer prevention : APJCP2025
Role of Circulating ARID1A mRNA as a Potential Biomarker in Female Breast Cancer Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly diagnosis of breast cancer is crucial for successful management and better disease outcomes. Using blood samples as a source of minimally invasive cancer biomarkers, is an essential research area. We aimed to evaluate the role of serum ARID1A mRNA as a circulating biomarker in breast cancer patients.
methodsThis case control study enrolled 60 newly diagnosed female breast cancer patients and 60 age matched control subjects. Total RNA extraction was performed from serum samples of all subjects, followed by reverse transcription and real time polymerase chain reaction for ARID1A gene expression. The expression level was studied for its correlation with different clinical and histopathological features of the study patients.
resultsSerum level of ARID1A mRNA was significantly lower in breast cancer patients than in control subjects (p<0.001). Median (min.-max.) of serum ARID1A in patients was 0.27 (0.005 - 3.92), versus 0.99 (0.27 - 3.53) in control subjects. Using ROC curve, ARID1A mRNA showed an AUC of 0.898, and 88.33% diagnostic sensitivity, 81.67% specificity. Low expression was significantly associated with increased tumor size, estrogen and progesterone receptor negativity, high Ki-67 labelling index, and high histological grade. No significant association was detected with HER2 status, tumor histopathological type, or lymph node spread.
conclusionARID1A mRNA in serum is a promising circulating biomarker that can help in diagnosis of breast cancer. Furthermore, the presented correlations indicate a potential prognostic value of serum ARID1A mRNA, where decreased level of this biomarker was associated with histopathological findings suggestive of a poor outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.